Escherichia coli as an antibody expression host for the production of diagnostic proteins: significance and expression. (4th July 2022)

• Record Type: Journal Article
• Authors: Huleani, Sergiu; Roberts, Michael R.; Beales, Lucy; Papaioannou, Emmanouil H.
• Is Part Of: Critical reviews in biotechnology. Volume 42:Number 5(2022)
• Page Start: 756
• Page End: 773
• Publication Date: 2022-07-04
• Subjects: Antibody fragments expression in E. coli -- expression plasmid -- affinity tags -- periplasmic antibody fragments expression -- E. coli cultures -- bioreactors -- scale-up; Biotechnology -- Periodicals; Biotechnology -- Periodicals; Review Literature -- Periodicals; Public Health -- Periodicals; Environment -- Periodicals; Industry -- Periodicals; Biotechnology; Review Literature; Public Health; Environment; Industry; 660.6
• DOI: 10.1080/07388551.2021.1967871
• Languages: English
• ISSNs: 0738-8551

Abstract

Abstract: This review article concerns the production of recombinant antibody fragments for applications mainly in the diagnostic sector. The so-called "point of care diagnostics" is very important for timely diagnosis and treatment, thus being able to save lives and resources. There is intense pressure for more accurate and less expensive rapid diagnostic tests, with a value preferably <$1. Thus, the large-scale cost-effective production of recombinant antibodies is vital. The importance of Escherichia coli toward the production of inexpensive rapid tests will be explained in this review paper. Details about the different strains of E. coli, the strategies used for the insertion and the expression of recombinant proteins, and the challenges that still exist are provided. Afterward, the importance of the expression scale and culture parameters in the final yield of the antibodies are examined. From this analysis, it appears that for good yields of recombinant antibodies, aside from appropriate gene transfer and expression, the culturing parameters are of paramount importance. Larger scale production is more favorable, mainly due to the higher cell densities that can be achieved. Yields of functional Fab fragments in the range of 10–20 mg/L are considered good in shake flasks, whereas in bioreactors can be up to 1–2 g/L. An amount of 10–500 mg of such antibody per million rapid tests is required. Despite the substantial importance of the production of the antibodies and their fragments, their downstream processing should be appropriately considered from the beginning for achieving the target value of the final rapid diagnostic tests.